Improvement in gross profit margin and ordinary profit margin
First written in FY2021. 5 of 17 entries say "Worsened", first in FY2023-Q3. Latest entry: 2026-10-15.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Gross profit for the fiscal year was ¥2.357590 billion, an increase of ¥397.273 million, or 20.3%, from the same period of the previous year. In the health food business, sales increased and plant utilization remained at record-high levels, resulting in an improved gross margin. In the chemicals business, gross margin improved as sales of high-value-added ion-exchange resin products grew.」
The improvement in gross profit and margins is specifically attributable to high utilization in health foods and sales of high-value-added products in chemicals. - FY2025-H1MitigatedAnnual report
「Revenue was ¥2.965030 billion, an increase of ¥52.705 million, or 1.8%, from the previous interim accounting period. Operating income was ¥154.486 million, up ¥39.170 million, or 34.0%; ordinary income was ¥171.117 million, up ¥61.030 million, or 55.4%; and interim net income was ¥120.705 million, up ¥27.471 million, or 29.5%.」
Company-wide revenue increased, and operating income, ordinary income and interim net income also increased year on year. By business, the figures also indicate improved cost ratios in health foods and a reduction in the operating loss in chemicals. - FY2024-Q3WorsenedAnnual report
「As a result, for the cumulative third quarter under review, net sales were ¥4,455.013 million, a decrease of ¥169.593 million, or 3.7%, year on year; operating income was ¥252.388 million, a decrease of ¥73.020 million, or 22.4%; ordinary income was ¥245.988 million, a decrease of ¥62.587 million, or 20.3%; and quarterly net income was ¥190.563 million, a decrease of ¥39.612 million, or 17.2%.」
Company-wide revenue declined, while operating income, ordinary income and quarterly net income also fell year on year, and earnings continued to deteriorate. - FY2024-Q2WorsenedAnnual report
「As a result, revenue for the cumulative second quarter was ¥2.912325 billion, a decrease of ¥208.920 million, or 6.7%, from the same period of the previous year. Operating income was ¥115.315 million, down ¥110.094 million, or 48.8%; ordinary income was ¥110.087 million, down ¥97.824 million, or 47.1%; and quarterly net income was ¥93.234 million, down ¥56.056 million, or 37.5%.」
Company-wide revenue declined, while operating income, ordinary income and quarterly net income also fell substantially year on year, and earnings continued to deteriorate. - FY2024-Q1WorsenedAnnual report
「Revenue was ¥1.516540 billion, a decrease of ¥9.926 million, or 0.7%, from the same period of the previous year. Operating income was ¥46.023 million, down ¥83.902 million, or 64.6%; ordinary income was ¥44.705 million, down ¥73.742 million, or 62.3%; and quarterly net income was ¥22.666 million, down ¥63.687 million, or 73.8%.」
While revenue remained nearly at the level of the same period of the previous year, operating income, ordinary income and quarterly net income declined substantially, indicating continued deterioration in earnings. - FY2023WorsenedAnnual report
「Gross profit for the fiscal year was ¥1.752057 billion, an increase of ¥19.251 million, or 1.1%, from the same period of the previous year. Margins declined owing to lower plant utilization in the health food business and changes in the product sales mix in the pharmaceuticals and chemicals businesses.」
Although revenue increased, margins declined owing to lower utilization at the health food plant and a higher proportion of lower-margin products, while operating income fell 15.5% year on year. - FY2023-Q3WorsenedAnnual report
「Revenue increased to ¥4.624606 billion, up ¥536.862 million, or 13.1%, from the same period of the previous year. Operating income was ¥325.409 million, down ¥29.361 million, or 8.3%; ordinary income was ¥308.576 million, down ¥46.163 million, or 13.0%; and quarterly net income was ¥230.175 million, down ¥69.561 million, or 23.2%.」
Although company-wide revenue increased, operating income, ordinary income and quarterly net income declined year on year, and earnings continued to deteriorate. - FY2023-Q2Deterioration in company-wide earningsAnnual report
「Operating income was ¥225.409 million, a decrease of ¥97.846 million, or 30.3%, from the same period of the previous year; ordinary income was ¥207.911 million, a decrease of ¥115.752 million, or 35.8%; and quarterly net income was ¥149.290 million, a decrease of ¥112.615 million, or 43.0%.」
Although the pharmaceuticals business recorded higher profit, company-wide earnings deteriorated year on year owing to losses in the health food and chemicals businesses, among other factors. - FY2023-Q1Margin decline in the pharmaceuticals business due to a higher proportion of imported APIsAnnual report
「Meanwhile, margins declined from the same period of the previous year because the proportion of imported APIs, which have relatively low margins, increased.」
In the pharmaceuticals business, sales of imported APIs increased, but the margin declined as the sales mix shifted toward relatively lower-margin products, and operating income fell 4.9% year on year. - FY2022Diverging margin trends by businessAnnual report
「Margins improved in the health food business owing to a recovery in sales and lower depreciation expenses, but deteriorated in the pharmaceuticals and chemicals businesses as the proportion of product sales with lower margins than in-house manufactured and processed products increased.」
Margins improved in health foods, while margins deteriorated in pharmaceuticals and chemicals as the proportion of lower-margin products sold increased, resulting in divergent trends by business. - FY2022-Q3Margin decline in the pharmaceuticals businessAnnual report
「Meanwhile, the products whose sales increased were mostly products with relatively low gross margins, resulting in a decline in the margin for the business as a whole.」
In the pharmaceuticals business, the overall business margin declined because most of the products whose sales increased had relatively low margins. - FY2022-Q2Margin decline in the chemicals businessAnnual report
「The margin for the business as a whole declined because the proportion of purchased products, which have lower margins than the company’s processed products, increased.」
In the chemicals business, the overall business margin declined as the proportion of lower-margin purchased products increased. - FY2021First statedAnnual report
「As described in “(1) Recognition, Analysis and Review of the Status of Operating Results, etc.” above, revenue declined in the 75th fiscal year, but gross profit and ordinary income increased, and gross margin and ordinary profit margin improved, owing to lower manufacturing costs and changes in the product sales mix.」
Gross margin improved from 30.0% to 33.4%, while ordinary profit margin improved from 5.3% to 6.9%.